• The initial focus will be on creating innovative topical treatments and drug therapies for healing wounds, easing itchiness, and preventive treatments for individuals with Epidermolysis Bullosa.
  • Dermaliq’s exclusive hyliQ® technology enables the contactless application of new drug therapies to delicate, sensitive, or diseased skin.

MUNICH and WILMINGTON, Del., May 28, 2025 — DEBRA Research gGmbH, a global non-profit dedicated to advancing research and drug development for Epidermolysis Bullosa (EB) patients, and Dermaliq Therapeutics, Inc., a dermatology company in clinical stages creating next-generation topical treatments, today announced a strategic, non-exclusive collaboration to improve cutaneous drug delivery into the skin for EB. The initial focus will be on improving therapies for wound-healing and anti-itch, as well as creating prophylactic treatments for EB sufferers. As part of the agreement, DEBRA Research has also invested strategically in Dermaliq.

EB is a group of rare and painful genetic skin conditions marked by extremely fragile skin, which leads to blisters and wounds from slight friction or injury. EB greatly impacts the daily lives of those affected and is linked to significant illness and death over time due to persistent wounds, infections, and problems involving internal organs. It is caused by mutations in genes that encode proteins responsible for the structural integrity of the skin. Currently, there is no cure, but new treatments are in development to manage symptoms, reduce pain, and improve quality of life.

Dermaliq is poised to transform therapeutic approaches for skin and wound management in EB. Through its proprietary hyliQ® technology, the company enables targeted delivery of active compounds into the skin without mechanical interference to delicate or wounded tissue. Applied without touching, hyliQ® is designed specifically for conditions like EB, where the skin is very delicate and likely to blister or be damaged from even slight friction. This innovative approach gives patients important therapeutic benefits by delivering effective treatments while protecting the integrity of compromised skin.

“This partnership closely aligns with our mission to speed up the creation of effective, high-impact therapies for people with EB,” said Dr Christoph Coch MD, Managing Director at DEBRA Research. “Dermaliq’s unique technology platform and clinical pipeline offer a promising way to overcome the limitations of current topical treatments, especially for application on the damaged and fragile skin common in EB. We believe this collaboration will be key in advancing transformative therapies and improving both medical results and quality of life for those affected by this devastating condition.”

“We are excited to join forces with DEBRA Research to bring our technology to an area with urgent and unmet medical needs,” said Frank Löscher, PhD, CEO of Dermaliq. “This partnership emphasizes our shared commitment to addressing the urgent needs of people living with this debilitating disorder. With its unique features and exceptional safety profile, hyliQ® is ideally suited for the touchless topical treatment of diseased and damaged skin. We look forward to the impact this collaboration can bring to the EB community and beyond.”

About DEBRA Research

DEBRA Research is a non-profit that aims to advance treatments and cures for EB, a rare and life-limiting genetic condition. As the research branch of DEBRA Austria – a patient organization created in 1995 to support individuals with EB – DEBRA Research works with academia, biotech, pharma, patient organizations, and regulatory bodies globally to drive innovation. DEBRA Research focuses on translational research and clinical development to meet the unmet needs of people with EB. Its goal is to speed up the discovery and development of treatments that improve quality of life, while working towards a future where EB is curable – a “world without EB.”

For more information, please visit and follow us on .

About Dermaliq Therapeutics

Dermaliq Therapeutics, Inc. is uniquely positioned to revolutionize topical dermatology. With our proprietary hyliQ® technology platform, we are overcoming traditional delivery barriers, enabling for the first time the targeted absorption into skin structures with unmatched bioavailability and cutaneous tolerability. This breakthrough paves the way for first-in-class and best-in-class topical treatments with broad application across dermatology and rare disease indications, offering substantial opportunities for long-term growth and value creation.

Dermaliq’s pipeline includes clinical stage assets in androgenetic alopecia, alopecia areata and wound healing.

For more information, visit .

Contacts

DEBRA Research GmbH
Dr Christoph Coch, Managing Director
Email:

Dermaliq Therapeutics, Inc.
Dr Frank Löscher, CEO
Email:

Media Inquiries

MC Services
Dr Cora Kaiser, Dr Johanna Kobler
Phone: +49 89 210 2280
Email: